Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children

Detalhes bibliográficos
Autor(a) principal: Woodard, Paul
Data de Publicação: 2011
Outros Autores: Carpenter, Paul A., Davies, Stella M., Gross, Thomas G., He, Wensheng, Zhang, Mei-Jie, Horn, Biljana N., Margolis, David A., Perentesis, John P., Sanders, Jean E., Schultz, Kirk R., Seber, Adriana [UNIFESP], Woods, William G., Eapen, Mary
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/33644
http://dx.doi.org/10.1016/j.bbmt.2010.08.016
Resumo: We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
id UFSP_5a47734c720efefd0ec3838a32b317d4
oai_identifier_str oai:repositorio.unifesp.br:11600/33644
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Woodard, PaulCarpenter, Paul A.Davies, Stella M.Gross, Thomas G.He, WenshengZhang, Mei-JieHorn, Biljana N.Margolis, David A.Perentesis, John P.Sanders, Jean E.Schultz, Kirk R.Seber, Adriana [UNIFESP]Woods, William G.Eapen, MaryMed Coll WisconsinAmgen IncFred Hutchinson Canc Res CtrCincinnati Childrens HospNationwide Childrens HospUniv Calif San FranciscoChildrens Hosp WisconsinUBCUniversidade Federal de São Paulo (UNIFESP)Aflac Canc Ctr & Blood Disorders Serv2016-01-24T14:06:25Z2016-01-24T14:06:25Z2011-05-01Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011.1083-8791http://repositorio.unifesp.br/handle/11600/33644http://dx.doi.org/10.1016/j.bbmt.2010.08.016WOS000290061500016.pdf10.1016/j.bbmt.2010.08.016WOS:000290061500016We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow TransplantationPublic Health Service from National Cancer Institute (NCI)National Heart, Lung and Blood Institute (NHLBI)National Institute of Allergy and Infectious Diseases (NIAID)NHLBINCIHealth Resources and Services Administration (HRSA/DHHS)Office of Naval ResearchAABBAetnaAmerican Society for Blood and Marrow TransplantationAmgen, Inc.Astellas Pharma US, Inc.Baxter International, Inc.Bayer HealthCare PharmaceuticalsBe the Match FoundationBiogen IDECBioMarin Pharmaceutical, Inc.Biovitrum ABBloodCenter of WisconsinBlue Cross and Blue Shield AssociationBone Marrow FoundationBuchanan Family FoundationCanadian Blood and Marrow Transplant GroupCaridianBCTCelgene CorporationCellGenix, GmbHCenters for Disease Control and PreventionChildren's Leukemia Research AssociationClinImmune LabsCTI Clinical Trial and Consulting ServicesCubist PharmaceuticalsCylex Inc.CytoThermDOR BioPharma, Inc.Dynal Biotech, an Invitrogen CompanyEisai, Inc.Enzon Pharmaceuticals, Inc.European Group for Blood and Marrow TransplantationGamida Cell, Ltd.GE HealthcareGenentech, Inc.Genzyme CorporationHistogenetics, Inc.HKS Medical Information SystemsHospira, Inc.Infectious Diseases Society of AmericaKiadis PharmaKirin Brewery Co., Ltd.The Leukemia & Lymphoma SocietyMerck CompanyMedical College of WisconsinMGI Pharma, Inc.Michigan Community Blood CentersMillennium Pharmaceuticals, Inc.Miller Pharmacal GroupMilliman USA, Inc.Miltenyi Biotec, Inc.National Marrow Donor ProgramNature Publishing GroupNew York Blood CenterNovartis OncologyOncology Nursing SocietyOsiris Therapeutics, Inc.Otsuka America Pharmaceutical, Inc.Pall Life SciencesPfizer IncSaladax Biomedical, Inc.Schering CorporationSociety for Healthcare Epidemiology of AmericaSoligenix, Inc.StemCyte, Inc.StemSoft Software, IncSysmex America, Inc.THERAKOS, Inc.Thermogenesis CorporationVidacare CorporationVion Pharmaceuticals, IncViraCor LaboratoriesViroPharma, Inc.Well-point, Inc.Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USAAmgen Inc, Thousand Oaks, CA USAFred Hutchinson Canc Res Ctr, Seattle, WA 98104 USACincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USANationwide Childrens Hosp, Columbus, OH USAUniv Calif San Francisco, Med Ctr, San Francisco, CA 94143 USAChildrens Hosp Wisconsin, Milwaukee, WI 53201 USAUBC, British Columbia Childrens Hosp, Vancouver, BC, CanadaInst Oncol Pediat, São Paulo, BrazilAflac Canc Ctr & Blood Disorders Serv, Childrens Healthcare Atlanta Egleston, Atlanta, GA USAUniversidade Federal de São Paulo, EPM, São Paulo, BrazilPublic Health Service from National Cancer Institute (NCI): U24-CA76518NHLBI: 5U01HL069294Health Resources and Services Administration (HRSA/DHHS): HHSH234200637015COffice of Naval Research: N00014-06-1-0704Office of Naval Research: N00014-08-1-0058Web of Science723-728engElsevier B.V.Biology of Blood and Marrow Transplantationhttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policyinfo:eu-repo/semantics/openAccessPediatric myelodysplastic syndromeUnrelated donorBone marrow transplantationUnrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Childreninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlereponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000290061500016.pdfapplication/pdf182280${dspace.ui.url}/bitstream/11600/33644/1/WOS000290061500016.pdfc51a91e18c3515ee1dbd83239a222fdfMD51open accessTEXTWOS000290061500016.pdf.txtWOS000290061500016.pdf.txtExtracted texttext/plain29105${dspace.ui.url}/bitstream/11600/33644/2/WOS000290061500016.pdf.txt345bec723f08ca9651b80443e08eb729MD52open access11600/336442022-11-04 14:18:43.812open accessoai:repositorio.unifesp.br:11600/33644Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:28:33.567683Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
title Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
spellingShingle Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
Woodard, Paul
Pediatric myelodysplastic syndrome
Unrelated donor
Bone marrow transplantation
title_short Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
title_full Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
title_fullStr Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
title_full_unstemmed Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
title_sort Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
author Woodard, Paul
author_facet Woodard, Paul
Carpenter, Paul A.
Davies, Stella M.
Gross, Thomas G.
He, Wensheng
Zhang, Mei-Jie
Horn, Biljana N.
Margolis, David A.
Perentesis, John P.
Sanders, Jean E.
Schultz, Kirk R.
Seber, Adriana [UNIFESP]
Woods, William G.
Eapen, Mary
author_role author
author2 Carpenter, Paul A.
Davies, Stella M.
Gross, Thomas G.
He, Wensheng
Zhang, Mei-Jie
Horn, Biljana N.
Margolis, David A.
Perentesis, John P.
Sanders, Jean E.
Schultz, Kirk R.
Seber, Adriana [UNIFESP]
Woods, William G.
Eapen, Mary
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.institution.none.fl_str_mv Med Coll Wisconsin
Amgen Inc
Fred Hutchinson Canc Res Ctr
Cincinnati Childrens Hosp
Nationwide Childrens Hosp
Univ Calif San Francisco
Childrens Hosp Wisconsin
UBC
Universidade Federal de São Paulo (UNIFESP)
Aflac Canc Ctr & Blood Disorders Serv
dc.contributor.author.fl_str_mv Woodard, Paul
Carpenter, Paul A.
Davies, Stella M.
Gross, Thomas G.
He, Wensheng
Zhang, Mei-Jie
Horn, Biljana N.
Margolis, David A.
Perentesis, John P.
Sanders, Jean E.
Schultz, Kirk R.
Seber, Adriana [UNIFESP]
Woods, William G.
Eapen, Mary
dc.subject.eng.fl_str_mv Pediatric myelodysplastic syndrome
Unrelated donor
Bone marrow transplantation
topic Pediatric myelodysplastic syndrome
Unrelated donor
Bone marrow transplantation
description We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
publishDate 2011
dc.date.issued.fl_str_mv 2011-05-01
dc.date.accessioned.fl_str_mv 2016-01-24T14:06:25Z
dc.date.available.fl_str_mv 2016-01-24T14:06:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/33644
http://dx.doi.org/10.1016/j.bbmt.2010.08.016
dc.identifier.issn.none.fl_str_mv 1083-8791
dc.identifier.file.none.fl_str_mv WOS000290061500016.pdf
dc.identifier.doi.none.fl_str_mv 10.1016/j.bbmt.2010.08.016
dc.identifier.wos.none.fl_str_mv WOS:000290061500016
identifier_str_mv Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011.
1083-8791
WOS000290061500016.pdf
10.1016/j.bbmt.2010.08.016
WOS:000290061500016
url http://repositorio.unifesp.br/handle/11600/33644
http://dx.doi.org/10.1016/j.bbmt.2010.08.016
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Biology of Blood and Marrow Transplantation
dc.rights.driver.fl_str_mv http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 723-728
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
bitstream.url.fl_str_mv ${dspace.ui.url}/bitstream/11600/33644/1/WOS000290061500016.pdf
${dspace.ui.url}/bitstream/11600/33644/2/WOS000290061500016.pdf.txt
bitstream.checksum.fl_str_mv c51a91e18c3515ee1dbd83239a222fdf
345bec723f08ca9651b80443e08eb729
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1783460238253359104